Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31637890 | 1.00 | ALDH1A1 (0.45) | ALDH1A1RECQLMAOACA1CA12 | |
| SCHEMBL31637791 | 0.91 | PDE2A (0.38) | ALDH1A1RECQLMAOANR1I2PDE3B | |
| SCHEMBL31638113 | 0.89 | FGFR1 (0.40) | ALDH1A1RECQLMAOAPDE3BPDE3A | |
| SCHEMBL18354456 | 0.85 | CA12 (0.39) | ALDH1A1CA1CA12CA9APP | |
| SCHEMBL179117 | 0.82 | KDM4E (0.46) | ALDH1A1CYP3A4SMN1; SMN2HTTRAB9A | |
| SCHEMBL21052284 | 0.82 | RAB9A (0.40) | MAOASMN1; SMN2APPIDO1HTT | |
| SCHEMBL30692844 | 0.82 | RAB9A (0.40) | MAOASMN1; SMN2APPIDO1HTT | |
| SCHEMBL3385321 | 0.81 | NPC1 (0.41) | ALDH1A1CA1CA12CA9CYP3A4 | |
| SCHEMBL25308169 | 0.79 | MAOA (0.44) | MAOASLC22A12APPSYKMAOB | |
| SCHEMBL15663115 | 0.79 | CYP2D6 (0.49) | CA1CA12CA9CYP3A4CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026909-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2023-01-26 | — | — | US | disclosed |
| US-20200339569-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2020-10-29 | — | — | US | disclosed |
| EP-3720851-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2020-10-14 | — | — | EP | disclosed |
| WO-2019110663-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2019-06-13 | — | — | WO | disclosed |
| WO-2004096804-A1 | DIAZABICYCLONONENE AND TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339569-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC6, HDAC1, HDAC3 | ALDH1A1 248/4885RECQL 2147/4885MAOA 955/4885 |
| US-20230026909-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC6, HDAC1, HDAC3 | ALDH1A1 248/4885RECQL 2147/4885MAOA 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.